smad4-dependent barrier constrains prostate cancer growth metastatic progression
effective clinical management prostate cancer pca challenged significant intratumoural heterogeneity genomic pathological levels limited understanding genetic elements governing disease progression exploited experimental merits mouse test hypothesis pathways constraining progression might activated indolent pten-null mouse prostate tumours inactivation progression barriers mice engender metastasis-prone condition comparative transcriptomic canonical pathway analyses followed biochemical confirmation normal prostate epithelium versus poorly progressive pten-null prostate cancers revealed robust activation tgf beta/bmp-smad4 signalling axis functional relevance smad4 supported emergence invasive metastatic lethal prostate cancers % penetrance upon genetic deletion smad4 pten-null mouse prostate pathological molecular analysis well transcriptomic knowledge-based pathway profiling emerging tumours identified cell proliferation invasion two cardinal tumour biological features metastatic smad4/pten-null pca model follow-on pathological functional assessment confirmed cyclin d1 spp1 key mediators biological processes together pten smad4 form four-gene signature prognostic prostate-specific antigen psa biochemical recurrence lethal metastasis human pca model-informed progression analysis together genetic functional translational studies establishes smad4 key regulator pca progression mice humans
